3Kosaka T,Yatabe Y,Endoh H,et al.Mutations of the epidermal growth factor receptor or gene in lung cancer:biological and clinical implications[J].Cancer Res,2004;64(24):8919-23.
4Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological feature associated with epidermal growth factor receptor gene mutations in lung cancers JNCI[J].Natl Cancer Inst,2005;97(5):339-46.
5Eberhard DA,Johnson BE,Amler LC,et al.Mutations in the ep-idermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J].J Clin Oncol,2005;23(25):5900-9.
6Tomizawa Y,Iijima H,Sunaga N,et al.Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer[J].Clin Cancer Res,2005;11(19):6816-22.
7Pao W,Wang TY,Riely GJ,et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib[J].Plos Med,2005;2(1):17.
8Shen YH,Zhang L,Gan Y,et al.Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling[J].J Biol Chem,2006;281(12):7727-36.
9Bianco R,Shin I,Ritter CA,et al.Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of receptor EGFR tyrosine kinase inhibitors[J].Oncogene,2003;22(18):2812-22.
10Wu Z,Gioeli D,Conaway M,et al.Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors[J].Prostate,2008;68(9):935-44.
二级参考文献23
1Marmor MD,Skaria KB,Yarden Y.Signal transduction and oncogenesis by ErbB/HER receptors.Int J Radiation Oncology Biol Phys,2004,58:903-913.
2Camp ER,Summy J,Bauer T,et al.Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.Clin Cancer Res,2005,11:397-405.
3Bianco R,Troiani T,Tortora G,et al.Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.Endocrine Related Cancer,2005,12:S159-S171.
4Thomson S,Buck E,Petti F,et al.Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.Cancer Res,2005,65:9455-9462.
5Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med,2004,350:2129-2139.
6Paez JG,Janne PA,Lee JC,et al.EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy.Science,2004,304:1497-1500.
7TracyS,Mukohara T,Hansen M,et al.Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer line H3255.Cancer Res,2004,64:7241-7244.
8Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci USA,2004,101:13306-13311.
9Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med,2005,352:786-792.
10Wang SE,Narasanna A,Perez-Torres M,et al.HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.Cancer Cell,2006,10:25-38.
6Janne PA.Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours[J].Lung Cancer,2008,60(2):s3-s9.
7Mok TS,Wu LL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,36(1):947-957.
8Douillard JY,Shepherd FA,Hirsh V,et al.Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell-lung-cancer:date from the randomized phase III INTEST trial[J].J Clin Oncol,2010,28(5):744-752.
9Cappuzzo F,Ciuleanu T,Stelmakh L,et al.Erlotinib as maintenance treatment in advanced non-small-cell-lung-cancer:a multicentre,randomised,placebo-controlled phase 3 study[J].Lancet Oncol,2010,11(6):521-529.
10Balak MN,Gong Y,Riely GJ,et al.Novel D761Y and common secondery T790M mutation lung adecarcinomar with acquired resistancr to kinase inhibitions[J].Clin Cancer Res,2007,13(11):3431-3432.
